GNCAQ
Genocea Biosciences Inc

8,517
Loading...
Loading...
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Genocea Biosciences Inc?
What is the 52-week high for Genocea Biosciences Inc?
What is the 52-week low for Genocea Biosciences Inc?
What is the 50-day moving average of Genocea Biosciences Inc?

Latest GNCAQ News

View
No GNCAQ news at the moment.

Advertisement|Remove ads.

Advertisement|Remove ads.